We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Parker-Hannifin
PH
$125B
| $28.5M | 0.21% |
73,126
+40,347
| +123% | +$13.7M |
|
127
Becton Dickinson
BDX
$43.1B
| $28.1M | 0.2% |
106,405
+28,803
| +37% | +$7.32M |
|
128
Verizon
VZ
$194B
| $27.7M | 0.2% |
745,502
+23,335
| +3% | +$864K |
|
129
Elevance Health
ELV
$81.9B
| $27.6M | 0.2% |
62,039
-39,336
| -39% | -$18.1M |
|
130
Citigroup
C
$222B
| $27.4M | 0.2% |
595,115
-100,417
| -14% | -$4.7M |
|
131
Xenon Pharmaceuticals
XENE
$6.32B
| $27.2M | 0.2% |
705,884
-13,322
| -2% | -$530K |
|
132
AstraZeneca
AZN
$263B
| $26.6M | 0.19% |
186,102
-117,924
| -39% | -$17.4M |
|
133
Ecolab
ECL
$75.6B
| $26.4M | 0.19% |
141,501
-83,397
| -37% | -$14.4M |
|
134
Kanzhun
BZ
$6.89B
| $26.2M | 0.19% |
1,739,530
-366,600
| -17% | -$6.13M |
|
135
Arista Networks
ANET
$219B
| $24.8M | 0.18% |
611,048
-2,992
| -0.5% | -$116K |
|
136
Pfizer
PFE
$140B
| $24.7M | 0.18% |
673,114
-690,431
| -51% | -$26.9M |
|
137
MongoDB
MDB
$24B
| $24.5M | 0.18% |
59,686
-34,351
| -37% | -$10M |
|
|
FISV
138
Fiserv Inc
FISV
$27.2B
| $23.5M | 0.17% |
186,672
+92,557
| +98% | +$10.9M |
|
139
Centene
CNC
$31.3B
| $23.3M | 0.17% |
345,806
+33,624
| +11% | +$2.24M |
|
140
Micron Technology
MU
$1.04T
| $23.3M | 0.17% |
369,470
+163,088
| +79% | +$10.5M |
|
141
Mettler-Toledo International
MTD
$26.8B
| $23.2M | 0.17% |
17,724
+5,067
| +40% | +$7.12M |
|
142
Progressive
PGR
$124B
| $23.1M | 0.17% |
174,517
-55,577
| -24% | -$7.45M |
|
143
Fortive
FTV
$19B
| $22.6M | 0.16% |
400,560
-51,290
| -11% | -$2.59M |
|
144
Tenable Holdings
TENB
$3.56B
| $22.2M | 0.16% |
509,808
| – | – |
|
145
General Mills
GIS
$19.2B
| $22.1M | 0.16% |
288,174
-55,231
| -16% | -$4.72M |
|
146
Insulet
PODD
$11.3B
| $22M | 0.16% |
76,140
+27,860
| +58% | +$8.46M |
|
147
Humana
HUM
$46.7B
| $21.7M | 0.16% |
48,600
+1,938
| +4% | +$976K |
|
148
Ionis Pharmaceuticals
IONS
$9.35B
| $21.5M | 0.16% |
524,067
+78,870
| +18% | +$3.03M |
|
|
XIFR
149
XPLR Infrastructure LP
XIFR
$1.18B
| $21.5M | 0.16% |
366,166
-254,847
| -41% | -$15.3M |
|
150
Synchrony
SYF
$23.7B
| $21.5M | 0.16% |
632,831
+406,207
| +179% | +$12.4M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.